Physician profile
Alexander Patterson
NPI 1629430822
$5,748.43
in general payments reported to CMS, 2019-2025
24 companies · $2,477 in 2025
The $2,477 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $286 · 2023: $1,251 · 2024: $1,734 · 2025: $2,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,451 · Education: $11.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,450.58 |
| Education | $11.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,060.43 | 2022-2025 | |
| Csl Behring | $718.84 | 2022-2025 | Haegarda, Hizentra, Andembry |
| Astrazeneca Pharmaceuticals LP | $672.30 | 2023-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $534.68 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $531.35 | 2022-2025 | Dupixent |
| Genentech USA, INC. | $349.02 | 2022-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $325.13 | 2022-2025 | Takhzyro, Cuvitru |
| Amgen INC. | $313.97 | 2022-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $234.15 | 2025 | Neffy |
| Blueprint Medicines Corporation | $170.25 | 2023-2025 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $145.73 | 2025 | |
| Pfizer INC. | $112.18 | 2022-2024 | |
| Kaleo, INC. | $82.03 | 2023-2024 | Auvi-Q |
| Biocryst US Sales Co., LLC | $73.91 | 2023-2025 | Orladeyo |
| Alk-Abello, INC | $70.34 | 2023-2024 | Timothy, Standardized, Standardized Mite D. Farinae, Pre-Pen |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $63.09 | 2023-2025 | |
| Pharming Healthcare, INC. | $63.03 | 2023-2025 | Ruconest |
| Cycle Pharmaceuticals INC | $51.78 | 2025 | Sajazir |
| Phadia US INC. | $44.91 | 2023-2024 | Immunocap |
| Ionis Pharmaceuticals, INC. | $37.92 | 2025 | Dawnzera |
| Azurity Pharmaceuticals, INC. | $32.02 | 2025 | Alvesco |
| Paratek Pharmaceuticals, INC. | $23.03 | 2025 | Xhance |
| Hikma Pharmaceuticals USA | $19.41 | 2025 | Ryaltris |
| Merck Sharp & Dohme LLC | $18.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.